Drugs / AMG 609
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04857606 | May 2021 → Jul 2023 | NAFLD1 | Amgen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 609 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857606 ↗ |
| Route | Subcutaneous | “Single dose of AMG 609 administered as a subcutaneous injection.” NCT04857606 ↗ |